Phase Ib Study of a Soluble Beta-glucan Odetiglucan in Combination with a CD40 Agonist (CDX-1140) in Patients with Metastatic Pancreatic Adenocarcinoma Whose Disease Did Not Progress During First-Line Chemotherapy
The purpose of this study is to evaluate the safety and feasibility of odetiglucan and CDX-1140 as maintenance therapy in patients with metastatic pancreatic adenocarcinoma.
Study ID: PGG-PAN2111
Trial Phase: Phase I
Trial Sponsor: HiberCell, Inc
Therapies Used in This Trial: CDX-1140